Functional cytotoxicity and infiltration capacity are critical benchmarks for testing immunotherapies in vitro.
In vitro co-culture assays in oncology research are used to obtain a better understanding of the interaction between cancer cells and the immune system in the tumor microenvironment and to determine how that environment plays a role through cellular interactions, cytokines and growth factors.
Historically, 2D monolayer cultures have been used in cancer research in vitro due to their high cell viability and ease of development, however, they lack the 3D microenvironment of the tissue itself. Our PD3D® co-culture assays support cross talk between multiple cell types and can mimic specific mechanisms shown in the tumor microenvironment. Many of our PD3D co-culture assays have been developed to utilize our well-characterized PD3D® bio bank models to drive this ex vivo system in combination with defined or mixed populations of allogeneic or autologous immune cells.
Careful assessment of immunomodulatory effects of new drugs in combination with already approved ones is crucial before these treatment regimens can be considered in the clinical setting. Due to unlimited possibilities of new combinations, especially in the view of synergy effect observed with double checkpoint inhibition blockade. cpo has developed a unique screening platform for immunoncology. Our automated and high throughput (384 well plate) platform allows for efficient and cost effective testing of these combinations in regards to the tumor – immune system interplay
If you want to test your cellular therapies, small molecules, bi-specific antibodies, immune checkpoint inhibitors, ADCs, vaccines and combinations of thereof please contact our experts